Median Technologies Launches a Capital Increase via a Private Placement - Seite 3

This press release is intended exclusively for information. This press release does not constitute and cannot be considered to constitute a public offering, an offer for subscription, an offer for sale or a solicitation of interest with a view to making a public offering of securities in any country whatsoever.

Securities can only be offered or sold in the United States of America after registration in accordance with the Securities Act, except pursuant to an exemption from the registration requirement. The Company’s securities subject to this press release have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offering of the securities subject to this press release in the United States of America.

The publication or distribution of this press release in certain countries may be prohibited under applicable laws. The information contained in this press release does not constitute an offer of securities in France, the United States of America, Canada, Australia or Japan or any other country. This press release is not intended to be published, released or distributed, directly or indirectly, in the United States of America, Canada, Australia or Japan. This document does not constitute an offer for sale or a public offering for Median Technologies shares in the United States of America or any other country.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by BPIfrance and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME), is listed on the Enternext PEA-PME 150 index. The company has been awarded the Euronext European Rising Tech label (2020). For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005751/en/